updat aasld nash franchis
attend aasld confer liver confer san francisco
met variou key opinion leader kol manag
cso cfo time opco colleagu jay olson nash kol panel note
street focu ceo search insight
focus gild/galapgo filgotinib recent finch readout
bud nash franchis project take center stage
multipl late-stag phase readout occur continu dilig
project uncov interest tidbit hope build
next month stay neutral
mani abstract aasld latest clinical-stag phase abstract
patel et al non-steroid farnesoid receptor fxr agonist
data demonstr efficaci drug said
slew compet approach mid/late-stag trial littl attent
paid late-stag trial approach
biggest pushback selonsertib phase clinic trial
stellar phase trial demonstr good efficaci
 reduct one stage fibrosi low- high-dos arm
respect trial lack placebo arm control arm fail nash
discuss cso think assert simtuzumab
essenti placebo merit ampl patient year data
simtuzumab two fail phase studi indic compare/
contrast question us whether phase patient popul
replic stellar focus
base dilig patient popul could similar due
inclusion/exclus criteria phase screen failur rate
efficaci signal seen phase ci high-dos selonsertib could
overcom specul bar us
could higher risk trial dilig continu
filgotinib believ earli lead best-in-class
glad hear cumul exposur lead safeti
signal rather select hope hold last manag
convers strengthen convict grow sale
hold above-median peer-group margin prepar potenti filgotinib/
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi stabil near term resurg
hiv busi growth addit kite axi-cel nash
off-set flat sales/non-gaap ep
opco model averag rel peer-group metric
believ risk/reward balanc
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
phase data pbc yescarta two-year
follow-up data tirabrutinib phase combo data r/r cll
phase data nash
selonsertib phase data nash
phase data cle sjogren syndrom
complet list catalyst exhibit
hcv sale trough next one two year stable/up
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
indicationdrugtimingmilestonehivvesatolimod phase studi hiv capsid phase phase data prephematology/oncologyyescarta axicabtagen enrol phase follow data enrol phase indol nhl phase combo enrol phase studi line dlbcl enrol phase phase pediatr phase studi enrol phase studi anti-bcma car-t registr studi base phase enrol phase studi mage solid ind tcr target solid endpoint phase combo studi r/r cllotherremdesivir phase studi ebola survivorsnash pbc psc stellar phase data stellar phase data fxr data pbccombin data atla phase studi selonsertib and/or and/or patient advanc fibrosi due enrol select phase studi phase finch studi phase finch studi divers studi enrol crohn phase studi cutan lupu phase studi sjogren syndrom inc
vosevi- hcv vemlidy- biktarvy- hiv total yescarta- selonsirtib- total total product perform na
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax inc
stock price compani mention report
